The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts

Journal of Thoracic and Cardiovascular Surgery

Volumn 127, Issue 5, 2004, Pages 1317-1322

  Wan, Song ^a   Yim, Anthony P C ^a   Johnson, Jason L ^b   Shukla, Nilima ^b   Angelini, Gianni D ^b   Smith, Frank C T ^b   Dashwood, Michael R ^c   Jeremy, Jamie Y ^b,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4,6 DIMETHYLPYRIMIDIN 2 YLOXY) 3,3 DIPHENYLBUTANOIC ACID; BSF 302146; CYCLINE; ENDOTHELIN 1; ENDOTHELIN 1A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; ENDOTHELIN A RECEPTOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; GRAFT FAILURE; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; SWINE; TISSUE SECTION; VASCULAR SMOOTH MUSCLE; VEIN GRAFT; ANASTOMOSIS; ANIMAL; COMMON CAROTID ARTERY; DRUG ANTAGONISM; DRUG EFFECT; INTIMA; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TRANSPLANTATION;

ADMINISTRATION, ORAL; ANASTOMOSIS, SURGICAL; ANIMALS; BENZHYDRYL COMPOUNDS; CAROTID ARTERY, COMMON; DOSE-RESPONSE RELATIONSHIP, DRUG; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; SAPHENOUS VEIN; SWINE; TUNICA INTIMA;

EID: 2342437620     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.06.018     Document Type: Article

References (28)

1. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1999;28:616-26.
2. Favaloro RG. Critical analysis of coronary artery bypass graft surgery: a 30-year journey. J Am Coll Cardiol. 1998;31:1B-63B.
3. Mortwani JG, Topol EJ. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation. 1998;97: 916-31.
4. Davies MG, Hagen P-O. Pathobiology of intimal hyperplasia. Br J Surg. 1995;81:1254-69.
5. Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol. 2000;15:395-9.
6. Davenport AP, Maguire JJ. The endothelin system in human saphenous vein graft disease. Curr Opin Pharmacol. 2001;1:176-82.
7. Trachtenberg JD, Sun S, Choi ET, Callow AD, Ryan US. Effect of endothelin infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol. 1993;22(suppl 8):S355-9.
8. Douglas SA, Vickery-Clark LM, Storer BL, Harty T, Louden C, Elliott JD, et al. A role for endogenous endothelin-1 in neointima formation following rat carotid artery balloon angioplasty: antiproliferative effects of the non-peptide endothelin receptor antagonist, SB 209670. Circ Res. 1994;75:190-7.
9. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller NL, Durham SK, et al. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon injured rat carotid arteries. J Cardiovasc Pharmacol. 1995;26:908-15.
10. Dashwood MR, Noertersheuser P, Kirchengast M, Munter K. Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: effect of the ETA receptor antagonist, LU 135252. Cardiovasc Res. 1999;43:445-56.
11. Dashwood MR, Mehta D, Izzat MB, Timm M, Bryan AJ, Angelini GD, et al. Distribution of endothelin-1 (ET) receptors [ET(A) and ET(B)]and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis. 1998;137:233-42.
12. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis. 2002;160:297-304.
13. Gray GA, Battistini B, Webb DJ. Endothelins are potent vasoconstrictors, and much more besides. Trends Pharmacol Sci. 2000;21:38-40.
14. Mehta D, George SJ, Jeremy JY, Izzat MB, Bryan AJ, Newby AC, et al. External stenting reduces long-term medial and neointimal thickening in a pig model of arteriovenous bypass grafting. Nat Med. 1998;4:235-9.
15. George SJ, Izzat MB, Gadsdon P, Johnson JL, Yim AP, Wan S, et al. The influence of external stent material on early neointimal formation and medial wall thickening in a model of saphenous vein bypass grafting. Atherosclerosis. 2001;155:329-36.
16. Porter KE, Dickinson T, London NJ. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition. J Vasc Surg. 2001;34:548-54.
17. Maguire JJ, Davenport AP. Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol. 1999;126:443-50.
18. Dobrin PB, Littoy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery. 1989;105:393-400.
19. Burnstock G. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat. 1999;194:335-42.
20. Wang DL, Wung BS, Peng YC, Wang JJ. Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells. J Cell Physiol. 1995;163:400-6.
21. Jeremy JY, Mehta D, Bryan AJ, Angelini GD. Platelets and saphenous vein graft failure. Platelets. 1997;8:295-309.
22. Cambiaggi C, Mencarelli M, Muscettola M, Grasso G. Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils. Cytokine. 2001;14:230-3.
23. Woods M, Bishop-Bailey D, Pepper JR, Evans TW, Mitchell JA, Warner TD. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells. J Cardiovasc Pharmacol. 1998;31(suppl 1): S348-50.
24. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev. 2003;8:107-15.
25. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999; 43:580-94.
26. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol. 1995; 146:819-26.
27. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105: 1890-6.
28. Langenfeld MR, Nakhla S, Death AK, Jessup W, Celermajer DS. Endothelin-1 plus oxidized low-density lipoprotein, but neither alone, increase human monocyte adhesion to endothelial cells. Clin Sci (Lond). 2001;101:731-8.